The bottom line: The overall picture of lower growth in infections and deaths continues but the decline has stalled somewhat lately in the countries hit worst, like Italy, Spain and the US. It points to a 'fat right tail' in new infections in these countries. We are still waiting for trial results on Remdesivir and Kevzara, which are set to come over the next week.

Read the full article on Danske Bank Research's website.